Intravenous Alteplase for Stroke in Those Older Than 80 Years Old

被引:156
作者
Ford, Gary A. [1 ]
Ahmed, Niaz [2 ]
Azevedo, Elsa [3 ]
Grond, Martin [4 ]
Larrue, Vincent [5 ]
Lindsberg, Perttu J. [6 ]
Toni, Danilo [7 ]
Wahlgren, Nils [2 ]
机构
[1] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Karolinska Univ Hosp, Karolinska Inst, Dept Neurol, Dept Clin Neurosci, Stockholm, Sweden
[3] Univ Porto, Stroke Grp, Hosp Sao Joao, Fac Med, P-4100 Oporto, Portugal
[4] Kreisklinikum Siegen, Dept Neurol, Siegen, Germany
[5] Toulouse Univ Hosp, Dept Neurol, Toulouse, France
[6] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland
[7] Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy
关键词
aging; elderly; stroke; thrombolysis; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; SAFE IMPLEMENTATION; SITS-MOST; THROMBOLYSIS; GREATER-THAN-OR-EQUAL-TO-80; TRIAL; ECASS;
D O I
10.1161/STROKEAHA.110.581884
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Risks and benefits of intravenous thrombolysis for patients with stroke >80 years of age are unclear. We examined outcomes and symptomatic intracerebral hemorrhage rates in <= 80-and >80-year-old patients in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register. Methods-We compared mortality and independence (modified Rankin Scale 0 to 2) at 3 months and symptomatic intracerebral hemorrhage (per Safe Implementation of Treatment in Stroke >= 4-point deterioration in National Institutes of Health Stroke Scale within 36 hours and Type 2 parenchymal hemorrhage and per National Institute of Neurological Disorders and Stroke [any increase in National Institutes of Health Stroke Scale and any hemorrhage]) of 1831 patients >80 years of age with 19 411 patients >80 years of age compliant with other European licensing criteria. Results-The >80-year-old group (median, 83 years) had more severe strokes (median National Institutes of Health Stroke Scale 14 versus 12), lower levels of prestroke independence (modified Rankin Scale 0 to 1, 82% versus 93%), and a larger proportion of females (59% versus 39%) compared with the younger group (68 years). Symptomatic intracerebral hemorrhage was not significantly increased after adjustment for other risk factors in those >80 years of age compared with those >80 years of age (per Safe Implementation of Treatment in Stroke 1.8% versus 1.7%, P=0.70, adjusted OR, 0.90, 95% CI, 0.73 to 1.09; P=0.28; per National Institute of Neurological Disorders and Stroke 9.5% versus 7.8%, P<0.005, adjusted OR, 0.96, 95% CI, 0.87 to 1.06, P=0.42). The patients >80 years of age had a higher mortality rate (30% versus 12%; P<0.005; adjusted OR, 1.53; 95% CI, 1.43 to 1.65; P<0.005) and reduced independence (35% versus 57%; P<0.005; adjusted OR, 0.73; 95% CI, 0.68 to 0.78; P<0.005). Conclusions-Selected patients with acute ischemic stroke >80 years of age otherwise fulfilling the intravenous alteplase license criteria have a similar rate of symptomatic intracerebral hemorrhage compared with younger patients and are appropriate candidates for thrombolysis. The higher mortality and the poorer functional outcome are consistent with the overall worse prognosis seen in the natural history of this age group. (Stroke. 2010;41:2568-2574.)
引用
收藏
页码:2568 / 2574
页数:7
相关论文
共 18 条
[1]  
[Anonymous], 1995, N. Engl J Med, V333, P1581, DOI DOI 10.1056/NEJM199512143332401
[2]   Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≥80 years) stroke patients [J].
Berrouschot, J ;
Röther, J ;
Glahn, J ;
Kucinski, T ;
Fiehler, J ;
Thomalla, G .
STROKE, 2005, 36 (11) :2421-2425
[3]   Stroke in the very old - Clinical presentation and determinants of 3-month functional outcome: A European perspective [J].
Di Carlo, A ;
Lamassa, M ;
Pracucci, G ;
Basile, AM ;
Trefoloni, G ;
Vanni, P ;
Wolfe, CDA ;
Tilling, K ;
Ebrahim, S ;
Inzitari, D .
STROKE, 1999, 30 (11) :2313-2319
[4]   Intravenous thrombolysis in stroke patients of ≥80 versus &lt;80 years of age -: a systematic review across cohort studies [J].
Engelter, Stefan T. ;
Bonati, Leo H. ;
Lyrer, Philippe A. .
AGE AND AGEING, 2006, 35 (06) :572-580
[5]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[6]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[7]   Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study [J].
Kammersgaard, LP ;
Jorgensen, HS ;
Reith, J ;
Nakayama, H ;
Pedersen, PM ;
Olsen, TS .
AGE AND AGEING, 2004, 33 (02) :149-154
[8]  
Kim D, 2007, AM J NEURORADIOL, V28, P159
[9]  
LORENZANO S, 2008, INT J STROKE S1, V1, P135
[10]  
Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO